Conformal Medical Steps Up Clinical Visibility in Left Atrial Appendage Closure at ISLAA and CRT 2026

Conformal Medical Inc is advancing its investigational left atrial appendage closure program with a prominent presence at two major cardiology meetings this week. The privately held medtech company is focused on stroke prevention in atrial fibrillation patients through its CLAAS AcuFORM LAAO System, which remains limited to clinical research use.

At the 14th Annual ISLAA Symposium in Los Angeles, Conformal is featured in a scientific session titled “Conformal & Study Updates” led by Dr. Thomas E. Waggoner of Pima Heart & Vascular. The session is expected to review progress in the company’s ongoing clinical studies and discuss the evolving role of LAAC therapy in structural heart care.

LinkedIn communications indicate that Conformal’s involvement at ISLAA centers on real‑world expertise, clinical insights, and collaboration with electrophysiologists and interventional cardiologists. This engagement is aimed at strengthening relationships with key opinion leaders and informing future trial design and product refinement.

In parallel, Conformal is highlighting its presence at the CRT 2026 cardiology conference in Washington, D.C., where more than 70 presentations will focus on left atrial appendage therapy. Conference materials underscore opportunities for clinicians to learn more about the CONFORM Pivotal Trial and the CLAAS AcuFORM LAAO System.

Across both meetings, the company reiterates that its device is an investigational technology not approved for commercial sale in the U.S. or abroad. As a result, Conformal remains in a development and validation phase, with near‑term performance tied to clinical milestones rather than product revenue.

For investors and stakeholders, the week’s news points to continued momentum in clinical development and physician outreach in a growing interventional cardiology niche. While regulatory and trial execution risks remain, Conformal’s increased visibility at specialized forums supports its long‑term positioning in the left atrial appendage closure market.